This Tiny Company Is Quietly Targeting Three Billion-Dollar Markets

April 23, 2025

Disseminated on behalf of Light AI Inc. Please Read Disclosures

(OHCFF.USOTC)

Dear Reader,

By now, you’ve heard the story: a revolutionary AI diagnostic tool that lives in your pocket. A 45-second scan. A 96.57% accuracy rate in detecting one of the world’s deadliest bacterial threats—Strep A. [i]

But let’s zoom out.

Because this isn’t just a medical breakthrough. It’s a business strategy designed to disrupt three separate healthcare markets at once.

That’s right. Light AI Inc. (OHCFF.USOTC) isn’t just building a better tool—they’re building a smarter company. One that doesn’t need to wait years for regulatory approval to scale. One that can generate revenue in multiple global markets with a single platform.

Let’s break it down.

Market #1: Lower Middle Income Countries (LMICs)

The first and most immediate opportunity for Light AI lies in parts of the world that have been historically underserved by traditional healthcare infrastructure. In many of these regions, hospitals are few and far between. Labs are unreliable. Trained doctors are overextended—or simply unavailable.

But you know what they do have?

Smartphones.

In many LMICs, mobile penetration rates exceed 80%. That’s millions—if not billions—of people walking around with a potential diagnostic device in their pocket.

And Light AI has already positioned itself to capitalize on this. Through a powerful partnership with Tech Care for All (TC4A)—a digital health platform that connects over 120,000 healthcare professionals in more than 20 countries—the company has a ready-made distribution network. [i]

They don’t need to build it. It’s already there.

That means Light AI can begin delivering its diagnostic tools into clinics and hospitals right now, while other medical device companies are still stuck in regulatory limbo.

Market #2: The Global Wellness Market

Here’s where the strategy gets even smarter.

Light AI’s diagnostic tool doesn’t just have to live in hospitals. Because while the U.S. healthcare system moves at a bureaucratic crawl, the consumer wellness space is exploding—with virtually zero red tape.

Fitness, wellness, and preventive care apps are downloaded by the millions. Major retailers and smartphone manufacturers are constantly seeking new health tech that can engage their customers in daily wellness routines.

And that’s exactly where Light AI fits.

Since their device is non-invasive, smartphone-based, and easy to use, it can be deployed as part of wellness initiatives through:

  • Pharmacy chains

  • Smartphone manufacturers

  • Telehealth platforms

  • Employer health programs

Best of all? This route doesn’t require FDA approval. [i]

That’s right—Light AI could begin generating consumer-facing revenue almost immediately. No delays. No gatekeepers.

North America already accounts for 57.14% of the global AI diagnostics market. That’s billions in potential revenue waiting to be unlocked. [viii]

And Light AI has the tech, the team, and the intellectual property to step in and claim a piece of it.

Market #3: The U.S. Healthcare System

Of course, the traditional route—entering the regulated healthcare system—is also on the table. And Light AI is making smart moves here, too.

They’re currently pursuing a De Novo application with the FDA. This process, designed for novel medical technologies, offers a clear and expedited path to approval. [i]

Once approved, Light AI would be able to sell its diagnostic device directly into:

  • Clinics

  • Urgent care centers

  • School-based health programs

  • Telemedicine providers

And the upside here is massive.

The AI diagnostics market in the U.S. alone is projected to hit $3.57 billion by 2033, growing at an annual rate of 20.84%. [viii]

Even more exciting: Light AI’s tool qualifies as a Software as a Medical Device (SaMD). This is a brand-new category in healthcare—and that means massive potential for early movers.

According to market research, companies that become “category kings” in new industries can claim up to 76% of the total market value. [ix]

If Light AI becomes that category king, early shareholders could see outsized returns.

Three Markets. One Platform. Limitless Upside.

Most healthcare startups focus on one thing—one niche, one customer, one market.

Light AI is different.

They’re building a platform that can operate in multiple sectors, serve a range of users, and scale globally without being bogged down by bureaucracy. That kind of flexibility is rare—especially in healthcare.

In just a few years, Light AI has:

  • Built a proprietary database of over 300,000 medical images [i]

  • Achieved clinical accuracy on par with Stanford-validated AI models [vii]

  • Secured patents in the U.S., EU, Australia, Canada, and Israel [i]

  • Raised over $18 million to fund their commercial rollout

Now, they’re poised to tackle a $12.65 billion diagnostics market with a product that costs a fraction of traditional lab tests—and works faster. [x]

In our next message, we’ll introduce you to the team behind Light AI—and explain why Microsoft, Google, and NVIDIA are pouring billions into this space.

This could be one of those moments investors look back on and say, “That’s when it all started.”

Light AI (OHCFF.USOTC) is on our radar right now. 

Kiyosaki Research

References

i LightAI Investor Presentation

ii "Superbugs could jeopardize food security for over two billion people", WOAH

iii "Antimicrobial Resistance (AMR)", World Bank

iv "AI in Healthcare Market Size, Share & Industry Analysis", Fortune Business Insights

v "The Potential Financial Benefits of AI in Healthcare Organizations", InfoTech

vi "Ten threats to global health in 2019", World Health Organization

vii "AI Medical Tools Show Promise as Health Tech Markets Rally", PYMNTS

viii "Artificial Intelligence in Diagnostics Market Size to Hit USD 8.54 Bn by 2033", BioSpace

ix “Category Design for Entrepreneurs: How to Become a Category King”, Category Pirates

x "AI in Diagnostics Market Size Skyrockets by 24.64% CAGR by 2034", Globe Newswire

xi "Artificial intelligence could save healthcare industry $360B a year", Healthcare Dive

xii "HealthTech Startups Valuation: Methods, Challenges and AI Adoption", Finrofca

xiii "2024 shaping up to be a big year for healthcare AI companies", Fierce Healthcare

xiv "A.I. Chatbots Defeated Doctors at Diagnosing Illness", New York Times

xv “New AAMC Report Shows Continuing Projected Physician Shortage”, AAMC

xvi "Artificial Intelligence in Medical Diagnostics Market to Hit USD 4.72 Billion by 2029", Yahoo Finance

IMPORTANT DISCLAIMER & DISCLOSURES

Investing in stocks is HIGH RISK. You could lose all of your investment.

Freedom Financial Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.

Please do not rely on the information presented by Freedom Financial Research as personal investment advice.

If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.

The communications from Freedom Financial Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.

Light AI Inc. is a paid sponsor of this report.

The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.

Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Freedom Financial Research nor any employee of Freedom Financial Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Freedom Financial Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.

DISCLAIMER: Freedom Financial Research, LLC (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Light AI Inc. made a one-time payment of fifty-five thousand USD to provide marketing services for a term of one week This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

Freedom Financial Research and its directors, employees, and members of their households do not own any shares of Light AI Inc. (OHCFF:US). However, Freedom Financial Research is extremely biased since this is a sponsored editorial.

HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.

NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Freedom Financial Research and all partners, members, and affiliates harmless in any event or claim. While Freedom Financial Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Freedom Financial Research is not obligated to update, correct, or revise the information post-publication.

FORWARD-LOOKING STATEMENTS: This article contains forward-looking statements about Light AI Inc., which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.